Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer

Molecular Oncology

Volumn 9, Issue 6, 2015, Pages 1155-1168

  Allensworth, Jennifer L ^a   Evans, Myron K ^a   Bertucci, François ^c   Aldrich, Amy J ^a   Festa, Richard A ^a   Finetti, Pascal ^c   Ueno, Naoto T ^d   Safi, Rachid ^a   McDonnell, Donald P ^a,b   Thiele, Dennis J ^a   Van Laere, Steven ^e   Devi, Gayathri R ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c INSTITUT PAOLI CALMETTES   (France)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e SINT AUGUSTINUS HOSPITAL   (Belgium)

Author keywords

ALDH; Antioxidant; Apoptosis; NF B; SUM149; XIAP

Indexed keywords

ALDEHYDE DEHYDROGENASE; AROMATASE INHIBITOR; CAPECITABINE; COPPER; DISULFIRAM; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IONOPHORE; LAPATINIB; MITOMYCIN; MITOXANTRONE; PEPTIDES AND PROTEINS; PROTEIN EIF4G1; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VINCA ALKALOID; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY BREAST CANCER; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TUMOR XENOGRAFT; DRUG EFFECTS; GENETICS; INFLAMMATORY BREAST NEOPLASMS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COPPER; DISULFIRAM; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; IONOPHORES; OXIDATIVE STRESS;

EID: 84929504218     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.02.007     Document Type: Article

References (50)

1. Abramoff M.D., Magalhaes P.J., Ram S.J. Image processing with ImageJ. Biophotonics Int. 2004, 11:36-42.
2. Aird K.M., Allensworth J.L., Batinic-Haberle I., Lyerly H.K., Dewhirst M.W., Devi G.R. ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res. Treat. 2012, 132:109-119.
3. Aird K.M., Ding X., Baras A., Wei J., Morse M.A., Clay T., Lyerly H.K., Devi G.R. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Mol. Cancer Ther. 2008, 7:38-47.
4. Aird K.M., Ghanayem R.B., Peplinski S., Lyerly H.K., Devi G.R. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. Mol. Cancer Ther. 2010, 9:1432-1442.
5. Allensworth J.L., Aird K.M., Aldrich A.J., Batinic-Haberle I., Devi G.R. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells. Mol. Cancer Ther. 2012, 11:1518-1527.
6. Allensworth J.L., Sauer S.J., Lyerly H.K., Morse M.A., Devi G.R. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-alpha-independent mechanism. Breast Cancer Res. Treat. 2013, 137:359-371.
7. Bellezza I., Mierla A.L., Minelli A. Nrf2 and NF-kappaB and their concerted modulation in Cancer pathogenesis and progression. Cancers 2010, 2:483-497.
8. Bertucci F., Ueno N.T., Finetti P., Vermeulen P., Lucci A., Robertson F.M., Marsan M., Iwamoto T., Krishnamurthy S., Masuda H., Van Dam P., Woodward W.A., Cristofanilli M., Reuben J.M., Dirix L., Viens P., Symmans W.F., Birnbaum D., Van Laere S.J. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann. Oncol. : Off. J. Eur. Soc. Med. Oncology/ESMO 2014, 25(2):358-365.
9. Brewer G.J. The use of copper-lowering therapy with tetrathiomolybdate in medicine. Expert Opin. Investig. Drugs 2009, 18:89-97.
10. Brown N.S., Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 2001, 3:323-327.
11. Cen D., Brayton D., Shahandeh B., Meyskens F.L., Farmer P.J. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J.Med. Chem. 2004, 47:6914-6920.
12. Charafe-Jauffret E., Ginestier C., Iovino F., Tarpin C., Diebel M., Esterni B., Houvenaeghel G., Extra J.M., Bertucci F., Jacquemier J., Xerri L., Dontu G., Stassi G., Xiao Y., Barsky S.H., Birnbaum D., Viens P., Wicha M.S. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res. 2010, 16:45-55.
13. Chen D., Cui Q.C., Yang H., Dou Q.P. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006, 66:10425-10433.
14. Croker A.K., Goodale D., Chu J., Postenka C., Hedley B.D., Hess D.A., Allan A.L. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J.Cell. Mol. Med. 2009, 13:2236-2252.
15. Dawood S., Cristofanilli M. Inflammatory breast cancer: what progress have we made?. Oncology (Williston Park, N.Y.) 2011, 25:264-270. 273.
16. Debeb B.G., Cohen E.N., Boley K., Freiter E.M., Li L., Robertson F.M., Reuben J.M., Cristofanilli M., Buchholz T.A., Woodward W.A. Pre-clinical studies of notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res. Treat. 2012, 134:495-510.
17. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., Qian D., Lam J.S., Ailles L.E., Wong M., Joshua B., Kaplan M.J., Wapnir I., Dirbas F.M., Somlo G., Garberoglio C., Paz B., Shen J., Lau S.K., Quake S.R., Brown J.M., Weissman I.L., Clarke M.F. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
18. Evans M.K., Tovmasyan A., Batinic-Haberle I., Devi G.R. Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase-independent cancer cell death. Free Radic. Biol. Med. 2013, 68c:302-314.
19. Faiman M.D., Jensen J.C., Lacoursiere R.B. Elimination kinetics of disulfiram in alcoholics after single and repeated doses. Clin. Pharmacol. Ther. 1984, 36:520-526.
20. Fraga C.G. Relevance, essentiality and toxicity of trace elements in human health. Mol. Aspects Med. 2005, 26:235-244.
21. Gorrini C., Harris I.S., Mak T.W. Modulation of oxidative stress as an anticancer strategy. Nature reviews. Drug Discov. 2013, 12:931-947.
22. Gupte A., Mumper R.J. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat. Rev. 2009, 35:32-46.
23. Hogarth G. Metal-dithiocarbamate complexes: chemistry and biological activity. Mini Rev. Med. Chem. 2012, 12:1202-1215.
24. Iwamoto T., Bianchini G., Qi Y., Cristofanilli M., Lucci A., Woodward W.A., Reuben J.M., Matsuoka J., Gong Y., Krishnamurthy S., Valero V., Hortobagyi G.N., Robertson F., Symmans W.F., Pusztai L., Ueno N.T. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res. Treat. 2011, 125:785-795.
25. Januchowski R., Wojtowicz K., Zabel M. The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed. Pharmacother. = Biomedecine Pharmacotherapie 2013, 67:669-680.
26. Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatrica Scand. Suppl 1992, 369:15-26.
27. Kashkar H. X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise. Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res. 2010, 16:4496-4502.
28. Klopp A.H., Lacerda L., Gupta A., Debeb B.G., Solley T., Li L., Spaeth E., Xu W., Zhang X., Lewis M.T., Reuben J.M., Krishnamurthy S., Ferrari M., Gaspar R., Buchholz T.A., Cristofanilli M., Marini F., Andreeff M., Woodward W.A. Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PloS One 2010, 5:e12180.
29. Manda G., Nechifor M.T., Neagu T.-M. Reactive oxygen species, Cancer and Anti-Cancer therapies. Curr. Chem. Biol. 2009, 3:22-46.
30. Masuda H., Brewer T.M., Liu D.D., Iwamoto T., Shen Y., Hsu L., Willey J.S., Gonzalez-Angulo A.M., Chavez-MacGregor M., Fouad T.M., Woodward W.A., Reuben J.M., Valero V., Alvarez R.H., Hortobagyi G.N., Ueno N.T. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann. Oncol. : Off. J. Eur. Soc. Med. Oncology/ESMO 2014, 25:384-391.
31. Mufti A.R., Burstein E., Duckett C.S. XIAP: cell death regulation meets copper homeostasis. Arch. Biochem. Biophys. 2007, 463:168-174.
32. Mulay I.L., Roy R., Knox B.E., Suhr N.H., Delaney W.E. Trace-metal analysis of cancerous and noncancerous human tissues. J.Natl. Cancer Inst. 1971, 47:1-13.
33. Nguyen D.M., Sam K., Tsimelzon A., Li X., Wong H., Mohsin S., Clark G.M., Hilsenbeck S.G., Elledge R.M., Allred D.C., O'Connell P., Chang J.C. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res. 2006, 12:5047-5054.
34. Nose Y., Kim B.E., Thiele D.J. Ctr1 drives intestinal copper absorption and is essential for growth, iron metabolism, and neonatal cardiac function. Cell Metab. 2006, 4:235-244.
35. Pena M.M., Koch K.A., Thiele D.J. Dynamic regulation of copper uptake and detoxification genes in Saccharomyces cerevisiae. Mol. Cell. Biol. 1998, 18:2514-2523.
36. Reeder N.L., Kaplan J., Xu J., Youngquist R.S., Wallace J., Hu P., Juhlin K.D., Schwartz J.R., Grant R.A., Fieno A., Nemeth S., Reichling T., Tiesman J.P., Mills T., Steinke M., Wang S.L., Saunders C.W. Zinc pyrithione inhibits yeast growth through copper influx and inactivation of iron-sulfur proteins. Antimicrob. Agents Chemother. 2011, 55:5753-5760.
37. Rizk S.L., Sky-Peck H.H. Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Res. 1984, 44:5390-5394.
38. Robertson F.M., Bondy M., Yang W., Yamauchi H., Wiggins S., Kamrudin S., Krishnamurthy S., Le-Petross H., Bidaut L., Player A.N., Barsky S.H., Woodward W.A., Buchholz T., Lucci A., Ueno N.T., Cristofanilli M. Inflammatory breast cancer: the disease, the biology, the treatment. CA: A Cancer J. clin 2010, 60:351-375.
39. Robinson J.S., Klionsky D.J., Banta L.M., Emr S.D. Protein sorting in Saccharomyces cerevisiae: isolation of mutants defective in the delivery and processing of multiple vacuolar hydrolases. Mol. Cell. Biol. 1988, 8:4936-4948.
40. Rueth N.M., Lin H.Y., Bedrosian I., Shaitelman S.F., Ueno N.T., Shen Y., Babiera G. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the national cancer database. J.Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol. 2014, 32:2018-2024.
41. Saigal K., Hurley J., Takita C., Reis I.M., Zhao W., Rodgers S.E., Wright J.L. Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy. Clin. Breast Cancer 2013, 13:335-343.
42. Silvera D., Arju R., Darvishian F., Levine P.H., Zolfaghari L., Goldberg J., Hochman T., Formenti S.C., Schneider R.J. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat. Cel. Biol. 2009, 11:903-908.
43. Singh S., Brocker C., Koppaka V., Chen Y., Jackson B.C., Matsumoto A., Thompson D.C., Vasiliou V. Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress. Free Radic. Biol. Med. 2013, 56:89-101.
44. Taminau J., Meganck S., Lazar C., Steenhoff D., Coletta A., Molter C., Duque R., de Schaetzen V., Weiss Solis D.Y., Bersini H., Nowe A. Unlocking the potential of publicly available microarray data using inSilicoDb and inSilicoMerging R/Bioconductor packages. BMC Bioinformatics 2012, 13:335.
45. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov. 2009, 8:579-591.
46. Van Laere S.J., Ueno N.T., Finetti P., Vermeulen P., Lucci A., Robertson F.M., Marsan M., Iwamoto T., Krishnamurthy S., Masuda H., van Dam P., Woodward W.A., Viens P., Cristofanilli M., Birnbaum D., Dirix L., Reuben J.M., Bertucci F. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res. 2013, 19:4685-4696.
47. Van Laere S.J., Van Der Auwera I., Van Den Eynden G.G., Elst H.J., Weyler J., Harris A.L., van Dam P., Van Marck E.A., Vermeulen P.B., Dirix L.Y. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res. 2006, 12:3249-3256.
48. Wang W., McLeod H.L., Cassidy J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. International journal of cancer. J.Int. du Cancer 2003, 104:504-511.
49. Williams K.P., Allensworth J.L., Ingram S.M., Smith G.R., Aldrich A.J., Sexton J.Z., Devi G.R. Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization. Cancer Lett. 2013, 337:77-89.
50. Yip N.C., Fombon I.S., Liu P., Brown S., Kannappan V., Armesilla A.L., Xu B., Cassidy J., Darling J.L., Wang W. Disulfiram modulated ROS-MAPK and NFkappaB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br. J. Cancer 2011, 104:1564-1574.